有一百多万日本儿童接受了由多家厂商制造、可能安全的新百日咳疫苗。与传统的全细胞疫苗不同(白喉-破伤风-百日咳免疫中的“P”成份;DTP),此新疫苗是部分纯化和去毒无细胞或提取的疫苗. 最近在美国贝塞斯达国立卫生研究院举行的有关新百日咳疫苗专题讨论会上,日本相应机构的木村报告了此疫苗对5,000名儿童临床试验.所有儿童都在2岁时开始了2次的免疫接种. More than one million Japanese children have received a new whooping cough vaccine that may be manufactured safely by many manufacturers. Unlike traditional whole-cell vaccines (diphtheria-tetanus-pertussis immunization “P” ingredient; DTP), this new vaccine is a partially purified and detoxified cell-free or extractable vaccine. Recently National Bethesda Health At its symposium on the new pertussis vaccine held by the Institute, Kimura from Japan’s corresponding agency reported clinical trials of the vaccine against 5,000 children, and all children started immunization twice at the age of 2.